THE-630 is a small molecule commercialized by Theseus Pharmaceuticals, with a leading Phase II program in Gastrointestinal Stromal Tumor (GIST). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of THE-630’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for THE-630 is expected to reach an annual total of $73 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
THE-630 is under development for the treatment of refractory KIT-mutant gastrointestinal stromal tumors (GIST). It is administered by oral route. The drug candidate is a next-generation, pan-variant proto oncogene c Kit (KIT) inhibitor.
Theseus Pharmaceuticals Overview
Theseus Pharmaceuticals is a biopharmaceutical company that develops and discovers therapies to overcome treatment-resistant cancer mutations. The company focuses on developing pan-variant tyrosine kinase inhibitors (TKIs) through its products. Its product pipeline includes THE-630, a KIT inhibitor for treatment of gastrointestinal stromal tumors (GIST); and fourth generation epidermal growth factor receptor (EGFR) inhibitor to address C797S-mediated resistance to first or later line osimertinib treatment of non-small cell lung cancer (NSCLC). The company is also evaluating several potential oncogene targets inhibitors for areas of unmet clinical needs. Theseus is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$27.3 million in FY2021, compared to an operating loss of US$6.8 million in FY2020. The net loss of the company was US$27.3 million in FY2021, compared to a net loss of US$12 million in FY2020.
For a complete picture of THE-630’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.